Eton Patent-Cliff Exposure & CMS Drug Spending Portfolio
Eton (US): 5 reconciled FDA prescription therapies (45.1% 2025 to 2030 cliff risk), $15.9M 2024 CMS Part D & Medicaid spend, and 23 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 45.1% |
| Primary Portfolio LOE Date | 2028-01-01 |
| 2024 CMS Total Public Spend | $15.9M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $15.9M |
| California HCAI SB 17 Filings | 23 WAC filings (max 1555.1% 2-yr change) |